OverviewSuggest Edit

Idorsia (formerly Actelion) is a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs. It targets a number of different diseases, such as Fabry disease, insomnia, resistant hypertension, cerebral vasospasm, epilepsy, nasal polyposis, systemic lupus erythematosus, and others. The company focuses on multiple therapeutic areas, including CNS, cardiovascular and immunological disorders, as well as orphan diseases.
TypePublic
Founded2017
HQAllschwil, CH
Websiteidorsia.com
Employee Ratings4

Latest Updates

Employees (est.) (Dec 2019)800(+7%)
Revenue (FY, 2019)CHF23.8 M(-60%)
Share Price (Sept 2021)CHF22.5
Cybersecurity ratingBMore

Key People/Management at Idorsia

Mathieu Simon

Mathieu Simon

Chairman, Executive Member
Martine Clozel

Martine Clozel

Executive Vice President, Chief Scientific Officer
André C. Muller

André C. Muller

Executive Vice President, Chief Financial Officer
Simon Jose

Simon Jose

Executive Vice President, Chief Commercial Officer
Jean-Paul Clozel

Jean-Paul Clozel

Chief Executive Officer
Guy Braunstein

Guy Braunstein

Executive Vice President, Head of Global Clinical Development
Show more

Idorsia Office Locations

Idorsia has offices in Allschwil, Shanghai, Lörrach and Chiyoda City
Allschwil, CH (HQ)
91 Hegenheimermattweg
Lörrach, DE
Marie-Curie-Straße 8
Show all (5)

Idorsia Financials and Metrics

Idorsia Revenue

Idorsia's revenue was reported to be CHF23.82 m in FY, 2019 which is a 60.7% decrease from the previous period.
CHF

Revenue (FY, 2019)

23.8m

Revenue growth (FY, 2018 - FY, 2019), %

(60.7%)

Net income (FY, 2019)

(494.6m)

EBIT (FY, 2019)

(482.4m)

Market capitalization (20-Sept-2021)

3.7b

Closing stock price (20-Sept-2021)

22.5

Cash (31-Dec-2019)

263.0m

EV

4.1b
Idorsia's current market capitalization is CHF3.7 b.
Annual
CHFFY, 2017FY, 2018FY, 2019

Revenue

158.1m60.6m23.8m

Revenue growth, %

(62%)(61%)

General and administrative expense

31.0m60.6m66.4m

R&D expense

134.9m370.1m438.5m
Half Year
CHFH1, 2017H1, 2018H1, 2019

Revenue

13.1m13.1m

General and administrative expense

2.3m29.1m32.1m

R&D expense

8.2m139.1m219.7m

Operating expense total

10.6m168.4m252.4m
Annual
CHFFY, 2017FY, 2018FY, 2019

Cash

622.5m798.6m263.0m

Prepaid Expenses

16.6m10.6m17.7m

Current Assets

881.3m941.4m775.4m

PP&E

156.7m150.7m150.7m
Quarterly
CHFQ2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

607.1m551.6m548.9m614.5m670.6m717.6m466.8m385.0m

Prepaid Expenses

5.6m

Current Assets

781.2m727.4m789.4m718.5m820.9m833.7m710.4m615.3m

PP&E

158.9m155.3m154.2m152.3m150.3m147.3m146.6m149.7m
Annual
CHFFY, 2017FY, 2018FY, 2019

Net Income

(15.3m)(387.5m)(494.6m)

Depreciation and Amortization

10.1m19.6m19.7m

Accounts Payable

21.3m2.4m417.0k

Cash From Operating Activities

95.5m(352.8m)(462.0m)
Quarterly
CHFQ2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

(11.4m)(82.7m)(78.9m)(159.6m)(278.9m)(106.7m)(232.4m)(352.6m)

Depreciation and Amortization

772.0k5.3m4.6m9.3m14.2m4.8m9.7m14.6m

Accounts Payable

14.9m6.9m(502.0k)5.7m3.6m15.3m10.7m4.6m

Cash From Operating Activities

4.4m(50.2m)(70.8m)(134.7m)(228.1m)(109.2m)(211.4m)(335.9m)
CHFQ2, 2017

Debt/Equity

0.5 x

Debt/Assets

0.3 x

Financial Leverage

1.6 x
Show all financial metrics

Idorsia Operating Metrics

FY, 2017FY, 2018FY, 2019

Projects in R&D Pipeline

111012

Workstations

550550550

Servers Deployed

150

Trial Master Files Migrated

35 k
Show all operating metrics

Idorsia Acquisitions / Subsidiaries

Company NameDateDeal Size
Idorsia Pharmaceuticals Deutschland GmbH
Idorsia Pharmaceuticals Japan Ltd
Idorsia Pharmaceuticals Ltd
Idorsia Pharmaceuticals US Inc
Idorsia (Shanghai) Pharmaceuticals Co., Ltd
Vaxxilon Ltd

Idorsia Cybersecurity Score

Cybersecurity ratingPremium dataset

B

84/100

SecurityScorecard logo

Idorsia Online and Social Media Presence

Embed Graph

Idorsia News and Updates

Idorsia successfully completes the offering of convertible bonds, securing funding to develop the company into a leading biopharmaceutical company

NOT FOR RELEASE, PUBLICATION, DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAWS.This announcement is not a prospectus and not an offer of securities for sale in any jurisdict…

Antares Pharma Announces Partner Idorsia Initiates the Phase 3 Study With Selatogrel for Acute Myocardial Infarction

EWING, N.J., June 28, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that its partner Idorsia Ltd (“Idorsia”) initiated its Phase 3 registration study to evaluate the efficacy and safety of self-administered subcuta…
Show more

Idorsia Frequently Asked Questions

  • When was Idorsia founded?

    Idorsia was founded in 2017.

  • Who are Idorsia key executives?

    Idorsia's key executives are Mathieu Simon, Martine Clozel and André C. Muller.

  • How many employees does Idorsia have?

    Idorsia has 800 employees.

  • What is Idorsia revenue?

    Latest Idorsia annual revenue is CHF23.8 m.

  • What is Idorsia revenue per employee?

    Latest Idorsia revenue per employee is CHF29.8 k.

  • Who are Idorsia competitors?

    Competitors of Idorsia include Roivant Sciences, Vifor Pharma and Ipsen.

  • Where is Idorsia headquarters?

    Idorsia headquarters is located at 91 Hegenheimermattweg, Allschwil.

  • Where are Idorsia offices?

    Idorsia has offices in Allschwil, Shanghai, Lörrach and Chiyoda City.

  • How many offices does Idorsia have?

    Idorsia has 5 offices.